Alpha Teknova(NASDAQ) TKNO

Alpha Teknova, Inc. makes ingredients for new medicines.

They help scientists grow cells and run laboratory tests.

These tools support the development of vaccines and therapies.

The Ingredients for Innovation

• Lab Essentials: Pre-poured plates, liquid media, and reagents for research; generated $9.2 million in revenue for the three months ended June 30, 2026.
• Clinical Solutions: Materials for diagnostic and therapeutic uses; generated $2.4 million in revenue for the three months ended June 30, 2026.
• Pre-poured Media Plates: Standard and custom gel plates used for growing and cloning cells.
• Liquid Culture Media: Specialized fluids and supplements that support the growth of microbial cells.
• Molecular Biology Reagents: Specialized chemicals used to clean, rehydrate, and purify biological samples in labs.

Strategic Steps and Funding

• Completed a registered direct offering and private placement in Sept. 2023.
• Closed a $15.4 million private placement in July 2024.
• Entered a new $28.2 million credit agreement in March 2025.
• Established a $225 million shelf registration statement in July 2025 for future funding.

What Sets Teknova Apart

Teknova uses proprietary manufacturing processes to create custom reagents with short turnaround times for its customers. Its facilities maintain ISO 13485:2016 certification, which allows the company to support biopharmaceutical production from research to commercialization.

Performance by the Numbers

• Revenue reached $12.2 million for the quarter ended June 30, 2026, up 18.5% year over year.
• Net loss was $3.2 million for the three months ended June 30, 2026, down 11.2% year over year.
• Clinical Solutions revenue increased 41.9% to $4.6 million during the six months ended June 30, 2026.
• Cash and short-term investments totaled $17.4 million as of June 30, 2026.
• Domestic sales in the United States represented 95.7% of total revenue for the quarter ended June 30, 2026.

Bottom Line

Teknova has transitioned from a general research supplier to a specialized provider for clinical-stage drug development. Its focus on custom manufacturing and quality certification supports its ongoing expansion within the biopharmaceutical market.